BIOCRYST PHARMACEUTICALS INC (BCRX) Stock Analyst Earnings Estimates
NASDAQ:BCRX - Nasdaq - US09058V1035 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 157.2M 783.15% | 270.8M 72.26% | 331.412M 22.38% | 458.8M 38.44% | 556.22M 21.23% | 633.27M 13.85% | 726.55M 14.73% | 807.12M 11.09% | 909M 12.62% | 1B 9.99% | 1.11B 11.03% | 1.189B 7.12% | |
| EBITDA YoY % growth | -176.92M -1.65% | -146.96M 16.93% | -100.506M 31.61% | 14.712M 114.64% | 60.727M 312.77% | 117.3M 93.16% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -177.7M -1.66% | -148.4M 16.49% | -102.161M 31.16% | 14.567M 114.26% | 71.323M 389.62% | 141.34M 98.17% | 241.22M 70.67% | 311.52M 29.14% | 409.88M 31.57% | 492.23M 20.09% | 611.52M 24.23% | 688.08M 12.52% | |
| Operating Margin | -113.04% | -54.80% | -30.83% | 3.18% | 12.82% | 22.32% | 33.20% | 38.60% | 45.09% | 49.23% | 55.09% | 57.87% | |
| EPS YoY % growth | -1.03 4.63% | -1.33 -29.13% | -0.99 25.56% | -0.36 63.51% | -0.09 74.87% | 0.29 422.06% | 0.88 200.91% | 1.20 36.23% | 1.60 33.83% | 2.01 25.12% | 2.54 26.56% | 2.81 10.71% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.06 79.24% | -0.07 59.72% | -0.04 34.43% | -0.03 52.12% | 0.00 105.84% | 0.01 108.94% | 0.05 234.82% | 0.06 288.68% | 0.07 1,821.92% |
| Revenue Q2Q % growth | 132.75M 42.13% | 129.17M 39.25% | 139.24M 27.36% | 142.47M 21.68% | 151.26M 13.94% | N/A | N/A | N/A | N/A |
| EBITDA Q2Q % growth | 15.836M 138.61% | 15.892M 212.06% | 12.373M 31.81% | 8.986M 4.14% | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | 9.211M 121.59% | 11.239M 177.57% | 15.973M 82.32% | 14.72M 91.37% | 20.861M 126.48% | N/A | N/A | N/A | N/A |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.07 63.16% | -0.07 | 0.00 | -6.50% |
| Q2 2024 Q2Q % growth | -0.06 75.00% | -0.18 | 0.12 | 66.23% |
| Q1 2024 Q2Q % growth | -0.17 39.29% | -0.22 | 0.05 | 20.98% |
| Q4 2023 Q2Q % growth | -0.28 26.32% | -0.25 | -0.03 | -12.50% |
| Q3 2023 Q2Q % growth | -0.19 17.39% | -0.24 | 0.05 | 20.19% |
| Q2 2023 Q2Q % growth | -0.24 25.00% | -0.23 | -0.01 | -3.06% |
| Q1 2023 Q2Q % growth | -0.28 30.00% | -0.30 | 0.02 | 8.14% |
| Q4 2022 Q2Q % growth | -0.38 -280.00% | -0.17 | -0.21 | -120.09% |
| Q3 2022 Q2Q % growth | -0.23 30.30% | -0.30 | 0.07 | 22.47% |
| Q2 2022 Q2Q % growth | -0.32 -33.33% | -0.35 | 0.03 | 8.62% |
| Q1 2022 Q2Q % growth | -0.40 -11.11% | -0.37 | -0.03 | -7.10% |
| Q4 2021 Q2Q % growth | -0.10 70.59% | -0.31 | 0.21 | 67.82% |
| Q3 2021 Q2Q % growth | -0.33 -26.92% | -0.30 | -0.03 | -9.92% |
| Q2 2021 Q2Q % growth | -0.24 | -0.25 | 0.01 | 2.26% |
| Q1 2021 Q2Q % growth | -0.36 -50.00% | -0.28 | -0.08 | -29.80% |
| Q4 2020 Q2Q % growth | -0.34 -1,600.00% | -0.26 | -0.08 | -32.96% |
| Q3 2020 Q2Q % growth | -0.26 23.53% | -0.26 | 0.00 | 0.16% |
| Q2 2020 Q2Q % growth | -0.24 29.41% | -0.26 | 0.02 | 7.89% |
| Q1 2020 Q2Q % growth | -0.24 14.29% | -0.25 | 0.01 | 3.04% |
| Q4 2019 Q2Q % growth | -0.02 | -0.26 | 0.24 | 92.36% |
| Q3 2019 Q2Q % growth | -0.34 | -0.33 | -0.01 | -4.53% |
| Q2 2019 Q2Q % growth | -0.34 | -0.32 | -0.02 | -7.53% |
| Q1 2019 Q2Q % growth | -0.28 | -0.28 | 0.00 | -0.84% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | 117.085M 34.98% | 114.75M | 2.335M | 2.03% |
| Q2 2024 Q2Q % growth | 109.332M 32.54% | 100.29M | 9.042M | 9.02% |
| Q1 2024 Q2Q % growth | 92.761M 34.87% | 87.317M | 5.444M | 6.23% |
| Q4 2023 Q2Q % growth | 93.401M 17.41% | 91.807M | 1.594M | 1.74% |
| Q3 2023 Q2Q % growth | 86.742M 14.39% | 87.673M | -931K | -1.06% |
| Q2 2023 Q2Q % growth | 82.491M 25.88% | 82.606M | -115K | -0.14% |
| Q1 2023 Q2Q % growth | 68.778M 37.78% | 73.111M | -4.333M | -5.93% |
| Q4 2022 Q2Q % growth | 79.55M 68.68% | 77.149M | 2.401M | 3.11% |
| Q3 2022 Q2Q % growth | 75.83M 85.00% | 76.117M | -287K | -0.38% |
| Q2 2022 Q2Q % growth | 65.53M 31.16% | 65.594M | -64K | -0.10% |
| Q1 2022 Q2Q % growth | 49.92M 161.91% | 52.387M | -2.467M | -4.71% |
| Q4 2021 Q2Q % growth | 47.16M 1,073.13% | 50.53M | -3.37M | -6.67% |
| Q3 2021 Q2Q % growth | 40.99M 571.97% | 40.885M | 105K | 0.26% |
| Q2 2021 Q2Q % growth | 49.96M 1,640.77% | 29.245M | 20.715M | 70.83% |
| Q1 2021 Q2Q % growth | 19.06M 295.44% | 9.067M | 9.993M | 110.21% |
| Q4 2020 Q2Q % growth | 4.02M -89.88% | 15.038M | -11.018M | -73.27% |
| Q3 2020 Q2Q % growth | 6.1M 242.70% | 3.677M | 2.423M | 65.90% |
| Q2 2020 Q2Q % growth | 2.87M 97.93% | 2.301M | 569K | 24.73% |
| Q1 2020 Q2Q % growth | 4.82M -18.17% | 4.376M | 444K | 10.15% |
| Q4 2019 Q2Q % growth | 39.73M | 10.074M | 29.656M | 294.38% |
| Q3 2019 Q2Q % growth | 1.78M | 3.024M | -1.244M | -41.14% |
| Q2 2019 Q2Q % growth | 1.45M | 2.06M | -610K | -29.61% |
| Q1 2019 Q2Q % growth | 5.89M | 3.172M | 2.718M | 85.69% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 21.07% | 21.07% | 4.3% | 4.87% |
| Revenue | 1.28% | 1.28% | 0% | 0.87% |